Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells

Journal of Gene Medicine

Volumn 14, Issue 12, 2012, Pages 776-787

  Matuskova, Miroslava ^a   Baranovicova, Lenka ^a   Kozovska, Zuzana ^a   Durinikova, Erika ^a   Pastorakova, Andrea ^b   Hunakova, Lubica ^a   Waczulikova, Iveta ^c   Nencka, Radim ^d   Kucerova, Lucia ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c Physics and Informatics   (Slovakia)

^d INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Bystander effect; Cancer gene therapy; Mesenchymal stromal cells; Retroviral vector

Indexed keywords

CYTOSINE DEAMINASE; FLUOROURACIL; GANCICLOVIR; PROTEIN; PROTEIN ABCC 11; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; BREAST CARCINOMA; BYSTANDER EFFECT; CANCER CELL CULTURE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; GLIOBLASTOMA; HELA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MELANOMA; MESENCHYMAL STROMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TREATMENT FAILURE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BYSTANDER EFFECT; CELL COMMUNICATION; CELL LINE, TUMOR; CELL SURVIVAL; CYTOSINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; FLUCYTOSINE; GANCICLOVIR; GAP JUNCTIONS; GENE EXPRESSION; GENE SILENCING; GENETIC VECTORS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; PENTOSYLTRANSFERASES; PRODRUGS; RETROVIRIDAE; THYMIDINE KINASE; TRANSDUCTION, GENETIC;

SIMPLEXVIRUS;

EID: 84871509846     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2684     Document Type: Article

References (43)

1. Bexell D, Scheding S, Bengzon J. Towards brain tumour gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 2010; 18: 1067-1075.
2. Roger M, Clavreul A, Venier-Julienne MC, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumours. Biomaterials 2010; 31: 8393-8401.
3. Aboody KS, Najbauer J, Danks MJ. Stromal and progenitor cell-mediated tumour selective gene therapy. Gene Ther 2008; 15: 739-752.
4. Kucerova L, Altanerova V, Matuskova M, Tyciakova S, Altaner C. Adipose tissue-derived mesenchymal stromal cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67: 6304-6313.
5. Kucerova L, Matuskova M, Pastorakova A, et al. Cytosine deaminase expressing human mesenchymal stromal cells mediated tumour regression in melanoma bearing mice. J Gene Med 2008; 10: 1071-1082.
6. Porthsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol. Asp. Med 2007; 28: 4-41.
7. Cihova M, Altanerova V, Altaner C. Stem cell based cancer gene therapy. Mol Pharm 2011; 3: 1480-1487.
8. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990; 39: 597-638.
9. Ramnaraine M, Pan W, Goblirsch M, et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 2003; 63: 6847-6854.
10. Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547-1554.
11. Wohlhueter RM, McIvor RS, Plagemann PG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into culutred mammalian cells. J Cell Physiol 1980; 104: 309-319.
12. Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stromal cells exert bystander effect on human glioblastoma cells. Cancer Lett 2010; 290: 58-67.
13. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
14. Freeman SM, Abboud CN, Whartenby K, et al. The bystander effect: tumour regression when a fraction of the tumour mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
15. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide gene therapy. Lancet 1997; 349: 2-3.
16. Gagendeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: involvement of an immunological component in the 'bystander effect'. Cancer Gene Ther 1996; 3: 83-88.
17. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumour natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthopic mouse model of prostate cancer. Cancer Res 1998; 58: 3221-3225.
18. Carystinos GD, Bier A, Batist G. The role of connexin-mediated cell-cell communication in breast cancer metastasis. J Mammary Gland Bio Neoplasia 2002; 6: 431-440.
19. Trosko JE, Madhukar BV, Chang CC. Endogenous and exogenous modulation of gap junctional intercellular communication: toxicological and pharmacological implications. Life Sci 1993; 53: 1-19.
20. Wolburg H, Rohlmann A. Structure-function relationships in gap junctions. Rev Cytol 1995; 157: 315-371.
21. Gakhar G, Schrempp D, Nguyen TA. Regulation of gap junctional intercellular communication by TCDD in HMEC and MCF-7 breast cancer cells. Toxicol Appl Pharmacol 2009; 235: 171-181.
22. Kandouz M, Batist Gap junctions and connexins as therapeutic targets in cancer. Expert Opin Ther Targets 2010; 4: 681-692.
23. Huang Q, Liu XZ, Kang CS, Wang GX, Zhong Y, Puhe PY. The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells Gene therapy with TK-BMSCs/GCV and Cx43. Cancer Gene Ther 2010; 17: 192-202.
24. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009; 29: 903-953.
25. Scartozzi M, Maccaron E, Giampieri R, et al. 5-fluorouracil pharmacogenomics: still rocking after all these years?. Pharmacogenomics 2011; 12: 251-265.
26. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
27. Adachi M, Sampath J, Lan LB, et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002; 277: 38998-39004.
28. Nambaru PK, Hübner T, Köck K, et al. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos 2011; 39: 132-139.
29. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005; 4: 855-863.
30. Oguri T, Bessho Y, Achiwa H, et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 2007; 6: 122-127.
31. Wilson BJ, Schatton T, Zhan Q, et al. ABCB5 identifies a therapy-refractory tumour cell population in colorectal cancer patients. Cancer Res 2011; 71: 5307-5316.
32. Lee TB, Choi CH. Detection of drug transporter expression using a 25-multiplex RT-PCR assay. Biotechnol Lett 2009; 31: 1485-1492.
33. Waczulikova I, Slezak P. Statistic in medical research. In Radiology IV. Bilicky J (ed). Veda: Bratislava, 2009.
34. Fritz V, Jorgensen C. Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stromal Cell Res Ther 2008; 3: 32-42.
35. Gentry BG, Im P, Boucher PD, Ruch RJ, Shewach DS. GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity. Gene Ther 2005; 12: 1033-1041.
36. Inaba M, Sawada H, Sadata A, Hamada H. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. Jpn J Cancer Res 1999; 90: 349-354.
37. Koyama F, Sawada H, Fuji H, et al. Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer 2000; 36: 2403-2241.
38. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 15: 3813-3822.
39. Beck A, Etienne MC, Chéradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30: 1517-1522.
40. Tanaka T, Duflot-Dancer A, Tiraby M, et al. Bystander effect from cytosine deaminase and uracil phosphoribosyltransferase genes in vitro: a partial contribution of gap junctions. Cancer Lett 2009; 282: 43-47.
41. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
42. Guo Y, Kotova E, Chen ZS, et al. ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′, 3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem 2003; 78: 29509-29514.
43. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.